{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/hypercholesterolaemia-familial/prescribing-information/statins-atorvastatin-rosuvastatin-simvastatin/","result":{"pageContext":{"chapter":{"id":"9c555b9e-f39b-567f-89ff-c983ab785087","slug":"statins-atorvastatin-rosuvastatin-simvastatin","fullItemName":"Statins (atorvastatin, rosuvastatin, and simvastatin)","depth":2,"htmlHeader":"<!-- begin field cf51e366-cf3a-440e-87e3-552ff0908121 --><h2>Statins (atorvastatin, rosuvastatin, and simvastatin)</h2><!-- end field cf51e366-cf3a-440e-87e3-552ff0908121 -->","summary":"","htmlStringContent":"<!-- begin item b7144819-8868-4c71-abaf-95f077744e13 --><!-- end item b7144819-8868-4c71-abaf-95f077744e13 -->","topic":{"id":"e1e436f3-28ca-5b97-8fd7-0156f61bfd7c","topicId":"030641a4-5f0a-4edf-a3ac-c21903c0095e","topicName":"Hypercholesterolaemia - familial","slug":"hypercholesterolaemia-familial","lastRevised":"Last revised in September 2020","chapters":[{"id":"23ce1270-bfbc-5ded-ab6d-c230787a3f98","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"1ac01f09-287f-5fd1-a1a5-3392235af19a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a92fc8a9-1061-5c02-bfff-d5f934ffdb53","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"93e2888f-005e-50e1-8f04-9c8023c43019","slug":"changes","fullItemName":"Changes"},{"id":"4cd7461b-b74a-5b4a-bbf9-499684c190d6","slug":"update","fullItemName":"Update"}]},{"id":"ebac4860-8279-5daa-8053-2376a8a9d71d","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"18209ebb-2e72-5f12-879c-4cac6c4a4a74","slug":"goals","fullItemName":"Goals"},{"id":"db603b52-871f-5820-9fbc-8fa05bcd0c1c","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"107217fb-afa8-59f5-b492-20a089b4ff48","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"55a1140b-b028-5056-9c88-5836bc15dd3b","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ef31a150-3669-5487-b7f5-e19d13bf639e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"00bd8dc2-4dee-5ba6-a759-82c99a58cd4d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"2cc20b8e-5159-51e2-b31b-9d3f16bcff36","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ec5f41d9-1fa0-53f1-aaee-0b37d62682af","slug":"definition","fullItemName":"Definition"},{"id":"687776fd-3a40-5dcf-ada0-1e58ff0f3128","slug":"causes","fullItemName":"Causes"},{"id":"cb1847cd-3321-5104-a764-beaf8c58397c","slug":"prevalence","fullItemName":"Prevalence"},{"id":"63b1cca3-87f7-5577-af56-fb3b38977e30","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"13588941-b46f-5306-a752-0527c4458410","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"4be7f4e2-6458-5112-948b-50b0e98bbb7a","slug":"identification","fullItemName":"Identification"},{"id":"343de6bd-ed4d-5fcc-b7d7-7ca1565daf0d","slug":"assessment-diagnosis","fullItemName":"Assessment and diagnosis"}]},{"id":"13ac6594-5e56-502b-96f4-2f848eb59c83","fullItemName":"Management","slug":"management","subChapters":[{"id":"2349db0e-12d5-5ff8-8e14-2e885307ad42","slug":"adults-with-heterozygous-fh","fullItemName":"Scenario: Adults with heterozygous FH"},{"id":"2f9228e9-d4af-55d1-937d-74e9c83e418e","slug":"adults-with-homozygous-fh","fullItemName":"Scenario: Adults with homozygous FH"},{"id":"c8ba3d52-d1bc-5e22-a366-a32ab938db00","slug":"children-young-people-with-fh","fullItemName":"Scenario: Children and young people with FH"}]},{"id":"323963cd-05be-519c-a523-3922e41f11f0","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"9c555b9e-f39b-567f-89ff-c983ab785087","slug":"statins-atorvastatin-rosuvastatin-simvastatin","fullItemName":"Statins (atorvastatin, rosuvastatin, and simvastatin)"},{"id":"8007ba2c-d902-5e52-9fb3-1aedd9470650","slug":"ezetimibe","fullItemName":"Ezetimibe"}]},{"id":"189143bc-5ae2-58d6-83ae-e0cd9bc01ee6","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"efd82555-8ecb-5170-be69-2e7390295832","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"652a4e82-a231-5cb4-8c7c-563ca0f43bbf","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"2be02b62-6acf-5570-854e-e6dcbfb36426","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"7d6217e2-3ab0-516c-97eb-53f4083e8805","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"2ce56158-d459-5b28-8343-7b6d776dc77a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"3f7dd940-f042-5f4d-8968-a8002af95e8d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"ca7fcd28-909d-579e-8783-9249cd67764f","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"323963cd-05be-519c-a523-3922e41f11f0","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"9a1fe36f-eccc-5d4f-a79d-b12523ce3c2b","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field bfb2c4c1-4e18-4253-80ea-579248714016 --><h3>What are the cautions and contraindications for atorvastatin, rosuvastatin, and simvastatin?</h3><!-- end field bfb2c4c1-4e18-4253-80ea-579248714016 -->","summary":"","htmlStringContent":"<!-- begin item ecffac53-5f5c-45cf-8834-233c2c07d3ba --><!-- begin field a4df511d-6014-4e6c-9eb2-99e23c609246 --><ul><li><strong>Do not prescribe statins</strong><strong> to:</strong><ul><li>People with active liver disease.</li><li>People with transaminase (alanine aminotransferase or aspartate aminotransferase) levels that are three or more times the upper limit of normal.</li><li>Pregnant women — lipid-modifying drugs may increase the risk of fetal malformation if taken during the first trimester.<ul><li>Inform all women and girls of childbearing age with familial hypercholesterolaemia (FH) that adequate contraception is required during treatment and for 1 month afterwards.</li><li>If they wish to conceive, they should stop treatment 3 months before attempting to conceive. In the event of an unplanned pregnancy, they should immediately stop treatment and seek medical advice.</li><li>If the woman is considering pregnancy or is pregnant, refer her for pre-pregnancy planning and antenatal care by an obstetrician <em>and</em>, if she is not already under their care, a specialist with expertise in FH <em>and </em>a cardiologist.</li><li>In the event of an unplanned pregnancy in a woman taking lipid-modifying drugs, stop treatment and refer urgently (to be seen within 14 days) to an obstetrician for fetal assessment.</li></ul></li><li>Breastfeeding women — manufacturers advise to avoid (no information available).</li></ul></li><li><strong>In addition:</strong><ul><li><strong>Do not prescribe rosuvastatin to people with:</strong><ul><li>A personal or familial history of hereditary muscular disorders.</li><li>Stage 4 or 5 chronic kidney disease (CKD, estimated glomerular filtration rate [eGFR] less than 30 mL/minute/1.73 m<sup>2</sup>).</li></ul></li><li><strong>Do not prescribe rosuvastatin 40 mg </strong><strong>to </strong><strong>people with predisposing factors for rhabdomyolysis, such as</strong> being of Asian origin, concomitant use with an <a class=\"topic-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/prescribing-information/statins-atorvastatin-rosuvastatin-simvastatin/#drug-interactions\">interacting</a> drug, stage 3 CKD (eGFR 30–60 mL/minute/1.73 m<sup>2</sup>), hypothyroidism, personal or family history of hereditary muscular disorders, previous history of muscular toxicity with another statin or a fibrate, and alcohol misuse. A maximum daily dose of 20 mg is recommended for this group of people.</li></ul></li><li><strong>Prescribe statins with caution to:</strong><ul><li>People with history of liver disease.</li><li>People with predisposing factors for rhabdomyolysis.<ul><li>Note that rosuvastatin 40 mg is contraindicated in this group of people (see above).</li></ul></li><li>People with a history of haemorrhagic stroke, particularly those with inadequately controlled hypertension — seek specialist advice before initiating a statin in this group of people.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">ABPI, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">BNF 76, 2018</a>]</p><!-- end field a4df511d-6014-4e6c-9eb2-99e23c609246 --><!-- end item ecffac53-5f5c-45cf-8834-233c2c07d3ba -->","subChapters":[]},{"id":"a06b1302-736b-5b82-81e6-fca2eaf559e7","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 2a0d28b7-4d87-4579-aef9-33cd4627ad7a --><h3>What are the adverse effects of atorvastatin, rosuvastatin, and simvastatin?</h3><!-- end field 2a0d28b7-4d87-4579-aef9-33cd4627ad7a -->","summary":"","htmlStringContent":"<!-- begin item 1fbe8f5c-6024-49cc-b66e-a128a890ccf3 --><!-- begin field c639fcee-0ba8-40dd-915a-ed22b8d3b975 --><ul><li><strong>Adverse effects of statins include:</strong><ul><li>Common or very common — asthenia, constipation, diarrhoea, dizziness, flatulence, gastrointestinal discomfort, headache, myalgia, nausea, sleep disorders, and thrombocytopenia.</li><li>Uncommon — alopecia, hepatic disorders, memory loss, pancreatitis, paraesthesia, sexual dysfunction, skin reactions, and vomiting.</li><li>Rare or very rare — peripheral neuropathy, tendinopathy, and serious muscular adverse effects (myopathy, myositis, and rhabdomyolysis).<ul><li>Although myalgia has been reported commonly in people receiving statins, muscle toxicity truly attributable to statin use is rare. When a statin is suspected to be the cause of myopathy, and creatine kinase (CK) concentration is markedly elevated or if muscular symptoms are severe, treatment should be discontinued.</li><li>If symptoms resolve and CK concentrations return to normal, reintroduce the statin at a lower dose and monitor the person closely.</li></ul></li><li>Frequency not known — depression, interstitial lung disease (characterized by dyspnoea, cough, and weight loss), and diabetes mellitus (in those at risk, including people with a history of hypertension, raised triglycerides, and a raised body mass index at baseline).<ul><li>Statins should not be discontinued if there is an increase in the blood-glucose concentration as the benefits continue to outweigh the risks.</li></ul></li></ul></li><li><strong>In addition for atorvastatin:</strong><ul><li>Common or very common — epistaxis, hyperglycaemia, hypersensitivity, joint disorders, laryngeal pain, muscle complaints, nasopharyngitis, and pain.</li><li>Uncommon — appetite decreased, burping, chest pain, fever, hearing impairment, hypoglycaemia, malaise, numbness, peripheral oedema, taste altered, vision disorders, and weight increased.</li><li>Rare or very rare — angioedema, gynaecomastia, and severe cutaneous adverse reactions (SCARs).</li></ul></li><li><strong>In addition for rosuvastatin:</strong><ul><li>Rare or very rare —<strong> </strong>arthralgia, gynaecomastia, haematuria, and polyneuropathy.</li><li>Frequency not known — cough, dyspnoea, oedema, proteinuria, Stevens-Johnson syndrome, and tendon disorders.</li></ul></li><li><strong>In addition for simvastatin:</strong><ul><li>Rare or very rare — acute kidney injury, anaemia, blurred vision and visual impairment, gynaecomastia, lichenoid drug eruptions, muscle cramps, and muscle rupture.</li><li>Frequency not known — cognitive impairment.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">BNF 76, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">MHRA, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">MHRA, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">ABPI, 2020a</a>]</p><!-- end field c639fcee-0ba8-40dd-915a-ed22b8d3b975 --><!-- end item 1fbe8f5c-6024-49cc-b66e-a128a890ccf3 -->","subChapters":[]},{"id":"53ec47ae-93c8-5492-8977-61d35f272ac5","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field e2112497-6819-4f70-88d1-f94bca0e9657 --><h3>What key drug interactions are associated with atorvastatin, rosuvastatin, and simvastatin?</h3><!-- end field e2112497-6819-4f70-88d1-f94bca0e9657 -->","summary":"","htmlStringContent":"<!-- begin item 081f7558-088f-4f41-8c37-9f63c69cbc5a --><!-- begin field 32476dc8-e422-47a7-96be-c6dd55c96d3a --><ul><li><strong>The following drugs increase the risk of rhabdomyolysis when given with certain statins </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">BNF 76, 2018</a>]<strong>:</strong><ul><li>Amiodarone<ul><li>Atorvastatin and simvastatin — manufacturers advise monitor and adjust statin dose.</li></ul></li><li>Colchicine <ul><li>Atorvastatin, rosuvastatin, and simvastatin — use with caution and adjust statin dose. </li></ul></li><li>Ezetimibe — manufacturers advise monitor for atorvastatin, rosuvastatin, and simvastatin.</li><li>Fibrates <ul><li>Atorvastatin — manufacturer advises monitor.</li><li>Rosuvastatin and simvastatin — manufacturers advise to adjust dose of the statin.</li></ul></li><li>Fusidic acid — the Medicines and Healthcare products Regulatory Agency (MHRA) advises that systemic fusidic acid should not be given with statins. <ul><li>If fusidic acid is essential, statins should be discontinued. They may be restarted 7 days after the last dose of fusidic acid. In exceptional cases requiring prolonged systemic fusidic acid treatment, the need for a statin should be assessed on an individual basis and only undertaken with close medical supervision.</li><li>People on concurrent treatment with a statin and fusidic acid should be advised to seek medical advice immediately if they experience any symptoms of muscle weakness, pain, or tenderness [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">MHRA, 2011</a>].</li></ul></li><li>Gemfibrozil — manufacturers advise avoid for atorvastatin, rosuvastatin, and simvastatin.</li><li>Ticagrelor — levels of simvastatin may be slightly increased. If both drugs are given concurrently, advise people to report any unexplained muscle pain, tenderness, or weakness. use a maximum, simvastatin dose of 40 mg daily [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">ABPI, 2020b</a>]. </li></ul></li><li><strong>The following </strong><strong>drugs</strong><strong> have been shown to lead to markedly increased concentrations of certain statins by c</strong><strong>ytochrome P450 enzyme inhibition</strong><strong>, resulting in a greatly increased risk of myopathy or rhabdomyolysis </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">BNF 76, 2018</a>]<strong>:</strong><ul><li>Ciclosporin<ul><li>Rosuvastatin and simvastatin — manufacturers advise avoid.</li><li>Atorvastatin — manufacturer advises monitor or adjust atorvastatin dose.</li></ul></li><li>Clarithromycin and erythromcyin<ul><li>Simvastatin — manufacturer advises avoid.</li><li>Atorvastatin — manufacturer advises avoid or adjust dose and monitor for rhabdomyolysis.</li></ul></li><li>Diltazem and verapamil<ul><li>Atorvastatin and simvastatin — manufacturers advise use with caution and adjust statin dose.</li></ul></li><li>Fluconazole<ul><li>Atorvastatin and simvastatin — manufacturers advise monitor and adjust dose.</li><li>Note that both fluconazle and statins can increase the risk of hepatotoxicity.</li></ul></li><li>Grapefruit juice<ul><li>Atorvastatin — advise against concomitant intake with large quantities (more than 1.2 L) of grapefruit juice [<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">Baxter, 2013</a>].</li><li>Simvastatin — manufacturer advises avoid.</li></ul></li><li>HIV protease inhibitors, including atazanavir, ritonavir, lopinavir, saquinavir, indinavir, and darunavir.<ul><li>Atorvastatin and rosuvastatin — manufacturers advise avoid or adjust dose and monitor for rhabdomyolysis.</li><li>Simvastatin — manufacturer advises avoid.</li></ul></li><li>Itraconazole and ketoconazole<ul><li>Atorvastatin — manufacturer advises avoid or adjust dose and monitor for rhabdomyolysis.</li><li>Simvastatin — manufacturer advises avoid.</li><li>Note that both itraconazole and statins can increase the risk of hepatotoxicity.</li></ul></li><li>Miconazole<ul><li>Atorvastatin — use with caution and adjust atorvastatin dose. </li><li>Simvastatin — manufacturer advises avoid.</li></ul></li></ul></li><li><strong>Other interactions include </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">BNF 76, 2018</a>]<strong>:</strong><ul><li>Warfarin —<strong> </strong>rosuvastatin possibly enhances the effects of warfarin.<ul><li>If concurrent use is necessary, monitor the international normalised ratio (INR) closely.</li></ul></li><li>Combined oral contraceptives (COCs) — although COCs are not contraindicated in women with familial hypercholesterolaemia (FH), other methods of contraception should be considered because of the potential increased risk of cardiovascular events with COC use. See the section on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-assessment/management/comorbidities-special-situations/#multiple-risk-factors-for-cardiovascular-disease\">Multiple risk factors for cardiovascular disease</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-assessment/\">Contraception - assessment</a> for information on choice of contraception for people with cardiovascular disease risk factors.<ul><li>The National Institute for Health and Care Excellence (NICE) recommends that prescribers should refer to the manufacturers' Summaries of Product Characteristics (SPCs) for individual drugs regarding potential interactions. However, evidence from one small study of concomitant use of rosuvastatin and a third generation combined oral contraceptives showed no decrease in contraceptive efficacy or lipid-lowering efficacy<em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/references/\">National Collaborating Centre for Primary Care, 2017</a>].</li></ul></li></ul></li><li><strong>For a complete list of possible drug interactions of all statins, </strong>see the <a href=\"http://scribe.clarity.co.uk/www.medicines.org.uk/emc\" data-hyperlink-id=\"5d1bd39e-1a5d-4822-a304-a98f017ff9da\">electronic Medicines Compendium</a> (eMC) or the <a href=\"https://bnf.nice.org.uk/\" data-hyperlink-id=\"eadda68c-df0e-46e1-aaa7-a98f017ffaca\">British National Formulary</a> (BNF).</li></ul><!-- end field 32476dc8-e422-47a7-96be-c6dd55c96d3a --><!-- end item 081f7558-088f-4f41-8c37-9f63c69cbc5a -->","subChapters":[]},{"id":"ea9783b1-7130-5e29-afea-1688ad6ae071","slug":"monitoring","fullItemName":"Monitoring","depth":3,"htmlHeader":"<!-- begin field cbf1d55e-f944-4e04-afb3-080354a493e2 --><h3>What monitoring is recommended for statins?</h3><!-- end field cbf1d55e-f944-4e04-afb3-080354a493e2 -->","summary":"","htmlStringContent":"<!-- begin item 93aed0c2-7cf6-441f-bf0a-56a242dbce54 --><!-- begin field b97986a3-ec9c-4b97-ae8c-c68661d44ebe --><ul><li><strong>Before initiating a statin, </strong>perform <a class=\"topic-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/management/adults-with-heterozygous-fh/#tests-before-drug-treatment\">baseline blood tests</a> to ensure that lipid-modification treatment is appropriate.</li><li><strong>After initiating a statin, </strong><a class=\"topic-reference internal-reference\" href=\"/topics/hypercholesterolaemia-familial/management/adults-with-heterozygous-fh/#follow-up\">follow up</a> the person to assess the effectiveness and tolerability of treatment.<ul><li><strong>Follow up should include:</strong><ul><li>Repeat liver function tests (LFTs) within 3 months of starting treatment, and again at 12 months.</li><li>Checking creatine kinase (CK) if unexplained muscle symptoms (such as pain, tenderness, or weakness) develop.</li></ul></li></ul></li></ul><!-- end field b97986a3-ec9c-4b97-ae8c-c68661d44ebe --><!-- end item 93aed0c2-7cf6-441f-bf0a-56a242dbce54 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}